SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, has appointed veteran medical technology finance executive Sarah M. Romano as chief financial officer, effective August 3, 2026. Romano brings more than two decades of experience in public-company finance, capital markets, and medical technology, having raised more than $100 million during her career. Her appointment comes as SS Innovations continues pursuing U.S. FDA clearance for its SSi Mantra surgical robotic system while expanding internationally.
Romano joins SS Innovations after serving as chief financial officer at Vicarious Surgical, another developer of robotic surgical technologies, where she oversaw financial and operational initiatives designed to reduce cash burn and strengthen the company’s balance sheet. Her expertise in capital markets and medtech finance is expected to support SS Innovations' strategic growth as it prepares for U.S. Food and Drug Administration review (https://nnw.fm/yY4UM). The company recently graduated the inaugural class of its SS International Centre for Robotics Surgery (“SSICRS”) cardiac robotic surgery training program, welcoming 33 healthcare professionals from seven countries.
The appointment underscores SS Innovations’ emphasis on surgeon education alongside technology deployment. The SSICRS program is designed to train surgeons in robotic-assisted procedures, addressing a critical need as robotic surgery adoption grows globally. By building a skilled workforce, the company aims to facilitate smoother integration of its SSi Mantra system into clinical practice. The training initiative also highlights SS Innovations’ commitment to expanding access to minimally invasive surgery, which can lead to reduced patient recovery times and improved outcomes.
SS Innovations’ focus on international expansion is evident in its recent activities. The company has been actively pursuing regulatory approvals in various markets, and the SSi Mantra system has already received clearance in several countries. With Romano’s financial leadership, the company is poised to navigate the complexities of global commercialization, including securing funding for R&D and market entry strategies. Her track record in raising capital will be instrumental as SS Innovations seeks to scale operations and compete with established players in the robotic surgery space.
The broader implications of this announcement extend to the healthcare industry, where robotic surgery is increasingly seen as a key area for innovation. SS Innovations’ efforts to combine technology with comprehensive training programs could set a benchmark for other companies in the field. As the company moves closer to FDA clearance, the appointment of a seasoned CFO like Romano signals to investors and partners that SS Innovations is serious about financial discipline and long-term value creation.
